Update information
May 2024: The wording of the recommendation describing the patient access scheme (see section 1.1) and in section 3.4 has been updated to include procurement information about ranibizumab biosimilars.
Minor changes since publication
February 2014: Implementation section updated to clarify that ranibizumab and pegaptanib are recommended as options for treating age-related macular degeneration.
ISBN: 978-1-4731-6142-9